144 related articles for article (PubMed ID: 1728598)
1. Cell kinetic analysis of human brain tumors by in situ double labelling with bromodeoxyuridine and iododeoxyuridine.
Hoshino T; Ito S; Asai A; Shibuya M; Prados MD; Dodson BA; Davis RL; Wilson CB
Int J Cancer; 1992 Jan; 50(1):1-5. PubMed ID: 1728598
[TBL] [Abstract][Full Text] [Related]
2. [Proliferation kinetics of human brain tumors by in situ double labeling with bromodeoxyuridine and iododeoxyuridine].
Maeda T; Hoshino T
No To Shinkei; 1992 Sep; 44(9):821-5. PubMed ID: 1476811
[TBL] [Abstract][Full Text] [Related]
3. Cell kinetics of rat 9L brain tumors determined by double labeling with iodo- and bromodeoxyuridine.
Asai A; Shibui S; Barker M; Vanderlaan M; Gray JW; Hoshino T
J Neurosurg; 1990 Aug; 73(2):254-8. PubMed ID: 2366082
[TBL] [Abstract][Full Text] [Related]
4. Cell kinetics of glial tumors.
Hoshino T
Rev Neurol (Paris); 1992; 148(6-7):396-401. PubMed ID: 1448658
[TBL] [Abstract][Full Text] [Related]
5. A new method for analyzing the cell kinetics of human brain tumors by double labeling with bromodeoxyuridine in situ and with iododeoxyuridine in vitro.
Shibuya M; Ito S; Davis RL; Wilson CB; Hoshino T
Cancer; 1993 May; 71(10):3109-13. PubMed ID: 8490840
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical double staining with immunogold-silver and alkaline phosphatase to identify nuclear markers of cellular proliferation.
Shibuya M; Ito S; Davis RL; Hoshino T
Biotech Histochem; 1993 Jan; 68(1):17-9. PubMed ID: 8383543
[TBL] [Abstract][Full Text] [Related]
7. S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine.
Hoshino T; Nagashima T; Cho KG; Murovic JA; Hodes JE; Wilson CB; Edwards MS; Pitts LH
Int J Cancer; 1986 Sep; 38(3):369-74. PubMed ID: 3527993
[TBL] [Abstract][Full Text] [Related]
8. Cell kinetics of human brain tumors: in vivo study with bromodeoxyuridine and flow cytometry.
Danova M; Riccardi A; Gaetani P; Wilson GD; Mazzini G; Brugnatelli S; Buttini R; Butti G; Ucci G; Paoletti P
Eur J Cancer Clin Oncol; 1988 May; 24(5):873-80. PubMed ID: 3169092
[TBL] [Abstract][Full Text] [Related]
9. Cell-kinetic characteristics of human brain tumors.
Assietti R; Butti G; Magrassi L; Danova M; Riccardi A; Gaetani P
Oncology; 1990; 47(4):344-51. PubMed ID: 2367061
[TBL] [Abstract][Full Text] [Related]
10. Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling.
Shibuya M; Hoshino T; Ito S; Wacker MR; Prados MD; Davis RL; Wilson CB
Neurosurgery; 1992 Apr; 30(4):494-7; discussion 497-8. PubMed ID: 1584346
[TBL] [Abstract][Full Text] [Related]
11. In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling.
Hoshino T; Nagashima T; Murovic JA; Wilson CB; Edwards MS; Gutin PH; Davis RL; DeArmond SJ
J Neurosurg; 1986 Mar; 64(3):453-9. PubMed ID: 3950723
[TBL] [Abstract][Full Text] [Related]
12. Correlation of histopathological features and proliferative potential of gliomas.
Germano IM; Ito M; Cho KG; Hoshino T; Davis RL; Wilson CB
J Neurosurg; 1989 May; 70(5):701-6. PubMed ID: 2709110
[TBL] [Abstract][Full Text] [Related]
13. [A review of cell kinetic studies on brain tumors with special reference to anti-bromodeoxyuridine monoclonal antibody method].
Nagashima T; Hoshino T
No Shinkei Geka; 1984 Aug; 12(9):1007-18. PubMed ID: 6390240
[TBL] [Abstract][Full Text] [Related]
14. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time.
Kakinuma K; Tanaka R; Onda K; Takahashi H
Acta Neurochir (Wien); 1998; 140(1):26-31; discussion 31-2. PubMed ID: 9522904
[TBL] [Abstract][Full Text] [Related]
15. Estimation of volume doubling time and cell loss in an experimental rat glioma model in vivo.
Nakajima M; Nakasu S; Morikawa S; Inubushi T
Acta Neurochir (Wien); 1998; 140(6):607-12; discussion 612-3. PubMed ID: 9755330
[TBL] [Abstract][Full Text] [Related]
16. Variability in the proliferative potential of human gliomas.
Hoshino T; Nagashima T; Cho KG; Davis RL; Donegan J; Slusarz M; Wilson CB
J Neurooncol; 1989 Jul; 7(2):137-43. PubMed ID: 2550593
[TBL] [Abstract][Full Text] [Related]
17. Proliferative characteristics of juvenile pilocytic astrocytomas determined by bromodeoxyuridine labeling.
Ito S; Hoshino T; Shibuya M; Prados MD; Edwards MS; Davis RL
Neurosurgery; 1992 Sep; 31(3):413-8; discussion 419. PubMed ID: 1407423
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of 201Tl SPECT in patients with glioma: a comparative study with histological diagnosis, clinical feature and proliferative activity].
Oriuchi N; Tamura M; Shibazaki T; Inoue T; Watanabe N; Tateno M; Tomiyoshi K; Hirano T; Igarashi H; Endo K
Kaku Igaku; 1991 Nov; 28(11):1263-71. PubMed ID: 1770641
[TBL] [Abstract][Full Text] [Related]
19. The clinical rationale for S-phase radiosensitization in human tumors.
McGinn CJ; Kinsella TJ
Curr Probl Cancer; 1993; 17(5):273-321. PubMed ID: 8281809
[TBL] [Abstract][Full Text] [Related]
20. Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 and BUdR labeling indices in human brain tumors.
Nishizaki T; Orita T; Furutani Y; Ikeyama Y; Aoki H; Sasaki K
J Neurosurg; 1989 Mar; 70(3):379-84. PubMed ID: 2536805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
